Abstracts tagged "Disease Activity"

Abstract Number: 1509 • ACR Convergence 2025
Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Shuzo Sato, Kaito Moriuchi, So Yamamoto, Hiroki Nibu, Takahito Sakamoto, Shotaro Ogawa, Kenji Saito, Yuya Sumichika, Shuhei Yoshida, Haruki Matsumoto, Jumpei Temmoku and Tomoyuki Asano, Fukushima Medical University, Fukushima, Fukushima, Japan
Background/Purpose: Past reports have shown that serositis is a risk factor for organ damage in patients with SLE. However, the distinct clinical features of newly…
Abstract Number: 2703 • ACR Convergence 2025
Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis
Ruoheng Zeng¹, Ryan Rebello², Konstanze Guggenberger³, Joshua Baker⁴, Shubhasree Banerjee⁴, Robert Kurtz⁴, Naomi Amudala⁴, Peter Merkel⁴ and Rennie Rhee⁴, ¹University of Pennsylvania School of Medicine, Philadelphia, PA, ²St. Joseph’s Hospital at McMaster University, Hamilton, ON, Canada, ³University Hospital of Wuerzburg, Wuerzburg, Germany, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is a need for better tools to monitor disease activity in giant cell arteritis (GCA). Prior studies demonstrated that vascular enhancement on cranial…
Abstract Number: 2404 • ACR Convergence 2025
Clinical features of Elderly-onset Systemic Lupus Erythematosus
Jessica Dai¹, Erin Carter², Mala Masson³, Amit Saxena⁴, H Michael Belmont⁵, Peter Izmirly⁶ and Jill Buyon⁴, ¹New York University Grossman School of Medicine, Tenafly, NJ, ²New York University Grossman School of Medicine, New York, NY, ³NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁴NYU Grossman School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶New York University Grossman School of Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic chronic disease characterized by a wide range of clinical and serological manifestations. It most commonly affects young…
Abstract Number: 2246 • ACR Convergence 2025
Different Populations, Different SDAI Cut-Off? A Proposal for a New Remission Threshold in Brazilian RA Patients from a National Multicenter Study
Lucas Pires¹, Alisson Pugliesi¹, Cleandro Pires², Ana Carolina Hidaka³, Vitor Cruz⁴, Manoel Barros Bertolo¹, Ana Paula Reis⁵, Rina Dalva Neubarth Giorgi⁶, Leticia Pereira⁷, Sebastião Cezar Radominski⁸, Ivanio Alves Pereira⁹, Maria Fernanda Brandão de Resende Guimarães¹⁰, Paulo Louzada Junior¹¹, Maria de Fátima Lobato da Cunha Sauma¹², Karina Bonfiglioli¹³, Claiton Viegas Brenol¹⁴, Licia Maria Henrique da Mota² and Geraldo da Rocha Castelar Pinheiro⁷, ¹Unicamp, Campinas, Brazil, ²UNB, Brasilia, Distrito Federal, Brazil, ³UNB, Brasilia, Brazil, ⁴UFG, Goias, Brazil, ⁵UniCEUB, Brasilia, Brazil, ⁶IAMSPE, São Paulo, Brazil, ⁷UERJ, Rio de Janeiro, Brazil, ⁸UFPR, Curitiba, Brazil, ⁹UFSC, Florianopolis, Brazil, ¹⁰UFMG, Belo Horizonte, Brazil, ¹¹USP-RP, Ribeirão Preto, Brazil, ¹²UFPA, Belem, Brazil, ¹³USP-SP, São Paulo, Brazil, ¹⁴UFRGS, Porto Alegre, Brazil
Background/Purpose: Remission criteria in Rheumatoid Arthritis (RA) have continuously evolved to balance the risks of both overtreatment and undertreatment. The most recent update includes the…
Abstract Number: 1661 • ACR Convergence 2025
Artificial Intelligence applied to Patient Reported Outcomes and Passive Physiologic Sensor Data can Accurately Classify Low Disease Activity in Rheumatoid Arthritis Patients
Jeffrey Curtis¹, Yujie Su², sam Barskiy³, Emily Holladay³, Shilpa Venkatachalam⁴, David Curtis⁵, Tapan Mehta³ and Fenglong Xie⁶, ¹Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Global Healthy Living Foundation, New York, NY, ⁵Global Healthy Living Foundation, Meriden, ⁶The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Remote therapeutic monitoring (RTM) and remote physiologic monitoring (RPM) programs have the potential to capture data between clinical visits and provide information back to…
Abstract Number: 1430 • ACR Convergence 2025
Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis
Stylianos Georgiadis¹, Lykke Ørnbjerg¹, Brigitte Michelsen², Tore K. Kvien², Mehrdad Shoae Kazemi¹, Bente Glintborg¹, Anne Gitte Loft³, Rita Fonseca⁴, Helena Santos⁵, Andreas Reich⁶, Anne C. Regierer⁶, Jarno Rutanen⁷, Laura Kuusalo⁸, Gary Macfarlane⁹, Gareth T. Jones⁹, Adrian Ciurea¹⁰, Michael J. Nissen¹¹, Bjorn Gudbjornsson¹², Olafur Palsson¹³, Ziga Rotar¹⁴, Katja Perdan Pirkmajer¹⁵, Daniela Di Giuseppe¹⁶, Merete Hetland¹⁷ and Mikkel Ostergaard¹⁸, ¹Rigshospitalet, Glostrup, Denmark, ²Diakonhjemmet Hospital, Oslo, Norway, ³Aarhus University Hospital, Aarhus, Denmark, ⁴Unidade Local de Saúde de Entre Douro e Vouga, Santa Maria da Feira, Portugal, ⁵Instituto Português de Reumatologia, Lisbon, Portugal, ⁶German Rheumatology Research Center, Berlin, Germany, ⁷Tampere University Hospital, Tampere, Finland, ⁸Turku University Hospital, Turku, Finland, ⁹University of Aberdeen, Aberdeen, United Kingdom, ¹⁰University Hospital Zurich, Zurich, Switzerland, ¹¹Geneva University Hospital, Geneva, Switzerland, ¹²Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹³University of Iceland, Reykjavik, Iceland, ¹⁴University Medical Centre Ljubljana, Ziri, Slovenia, ¹⁵University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁶Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Stockholms Lan, Sweden, ¹⁷Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ¹⁸Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark
Background/Purpose: In patients with axial spondyloarthritis (axSpA), high disease activity is a key indication for biological disease-modifying antirheumatic drug (bDMARD) initiation. The Axial Spondyloarthritis Disease…
Abstract Number: 1310 • ACR Convergence 2025
Naturalized Language Processing Based Extraction of Rheumatoid Arthritis Disease Activity Measures from the Electronic Health Record
Elizabeth Park¹, Iram Kamdar², Reid Weisberg¹, Andy Nguyen¹, Joan Bathon³, Jon Giles⁴, Chunhua Weng⁵ and Elana Bernstein¹, ¹Columbia University Irving Medical Center, New York, NY, ²Columbia University Data Science Institute, New York, NY, ³Columbia University, NEW YORK, NY, ⁴Cedars-Sinai Medical Center, New York, NY, ⁵Columbia University Department of Biomedical Informatics, New York, NY
Background/Purpose: A treat-to-target approach in rheumatoid arthritis (RA) requires intense monitoring of RA disease activity with measures such as the clinical disease activity index (CDAI).…
Abstract Number: 0620 • ACR Convergence 2025
The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
Luis Daniel Fajardo Hermosillo and María Karina Lizbeth López Ramírez, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, GUADALAJARA, Jalisco, Mexico
Background/Purpose: Remission in Systemic Lupus Erythematosus (SLE) is described by the Definition of Remission in SLE (DORIS), but it is hardly achieved in clinical practice,…
Abstract Number: 0493 • ACR Convergence 2025
Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers with CIT-013, a First in Class NETosis Inhibitor
Maarten Kraan¹, Salah Hadi², Leonie Middelink³, Renato Chirivi³, Eric meldrum³, Naomi Klarenbeek⁴ and Patrick Round³, ¹Citryll BV, Den Dolder, Netherlands, ²ICON Netherlands BV, Groningen, Netherlands, ³Citryll BV, Oss, Netherlands, ⁴CHDR, Leiden, Netherlands
Background/Purpose: Aberrant Neutrophil Extracellular Trap (NET) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases including rheumatoid arthritis (RA). We report data of…
Abstract Number: 0391 • ACR Convergence 2025
Which score fits best? Correlation of clinical indices of Disease Activity and Ultrasound findings in Juvenile Idiopathic Arthritis during Transitional Care
Andrea Pilato¹, Giusyda Tarantino², Maria Isabella Petrone², Angela Aquilani², Emiliano Marasco², Rebecca Nicolai², Fabrizio De Benedetti³, Roberto Giacomelli⁴, Luca Navarini¹ and Silvia Magni-Manzoni², ¹University of Rome Campus Bio-Medico, Rome, Italy, ²Bambino Gesù IRCCS Children's Hospital, Rome, Italy, ³Bambino Gesu Children's Hospital, Rome, Rome, Italy, ⁴i) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Biomedico; ii) Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome "Campus Bio-Medico", Rome, Italy
Background/Purpose: Monitoring disease activity is a crucial aspect of the treat to target paradigm in the management of rheumatic diseases. There are no standardized protocols…
Abstract Number: 2686 • ACR Convergence 2025
Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.
Koray Tascilar¹, Alp Temiz¹, Filippo Fagni², Arnd Kleyer³, Louis Schuster¹, Stephan Kemenes¹, Sara Bayat¹, David Simon⁴ and Georg Schett⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ³Charite Universitätsmedizin Berlin, Erlangen, Bayern, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁵Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: RA and PsA follow different pathomechanisms and incur disease-specific erosive and osteoproliferative bone changes. We used data from a large cohort of RA and…
Abstract Number: 2366 • ACR Convergence 2025
Association Between Skin and Joint Symptom Control and Patient-Reported Pain and Health Status Among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Skyler Peterson⁴, Robert Low³ and Alexis Ogdie⁵, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴CorEvitas, LLC, Waltham, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory condition primarily affecting the joints and skin.1 More severe symptoms are associated with lower health-related quality of…
Abstract Number: 2158 • ACR Convergence 2025
Evaluating Nailfold Capillary Changes as Indicators of Disease Activity in Juvenile Dermatomyositis
Zilan Zheng¹, Laila Metni², Susan Kim³ and Jessica Neely⁴, ¹University of California, San Francisco, San Francisco, CA, ²University of California, Berkeley, Berkeley, CA, ³UCSF Benioff Children's Hospital, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare pediatric autoimmune myopathy characterized by skin and muscle inflammation, resulting in microvascular changes that can be visualized in…
Abstract Number: 1608 • ACR Convergence 2025
Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Christian Pagnoux⁸, Ulrich Specks⁹, Benjamin Terrier¹⁰, Lena Börjesson Sjö¹¹, Priya Jain¹², Aadarsh Lal¹³, Sofia Necander¹⁴, Claire Walton¹⁵ and Michael Wechsler¹⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ⁹Mayo Clinic, Rochester, MN, ¹⁰Cochin Hospital, Paris, France, ¹¹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹²BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹³Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹⁴Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁵Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁶Department of Medicine, National Jewish Health, Denver
Background/Purpose: Results from the 1-year double-blind period and first year of the open-label extension (OLE) of the MANDARA trial (NCT04157348) demonstrated that over 60% of…
Abstract Number: 1421 • ACR Convergence 2025
Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”)
Lily Mikolajczak¹, Helena Kuhn¹, Leslie Harrold² and George Reed³, ¹Kuchnir Dermatology and Dermatologic Surgery, Milford, MA, ²CorEvitas, Northborough, MA, ³University of Massachusetts Chan Medical School, Worcester, MA
Background/Purpose: Patients with psoriatic arthritis often report having brain fog, describing symptoms such as forgetfulness, difficulty thinking and memory issues. It has been hypothesized that…

« Previous Page
1
…
5
6
7
8
9
…
112
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].